Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Alterations in Muscle Tone ll01:12

Alterations in Muscle Tone ll

Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proton Beam Therapy for Intracranial Germ Cell Tumors in Pediatric, Adolescent, and Young Adult Patients: A Single-Center Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Hands down, early wins: the case for active, play and training based therapies in unilateral cerebral palsy.

Pediatric research·2025
Same author

An exploratory study of functional brain activity associated with gross motor function improvement in children with unilateral cerebral palsy.

Developmental neurorehabilitation·2024
Same author

Changes in nutritional status and the development of obesity and metabolic syndrome following pediatric heart transplantation.

Pediatric transplantation·2024
Same author

Using the capability, opportunity, and motivation model of behaviour to assess provider perception of implementing solution-focused goal-setting in paediatric rehabilitation.

Journal of child health care : for professionals working with children in the hospital and community·2023
Same author

Hepatitis B related hepatocellular carcinoma. Screening, screening and more screening.

Irish medical journal·2023
Same journal

Ictal Asystole or Vasovagal Syncope? A Diagnostic Pitfall in Pediatric Drug-Resistant Epilepsy.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Validation of an ICD-10 Code for Diplopia in the Emergency Department: A Retrospective Cohort Study.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Practice Patterns and Care Gaps in Lennox Gastaut Syndrome: A call for Action.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Isolated Achiasma Discovered at Age 86: A Rare Cause of see-saw nystagmus and bitemporal hemianopia.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Post-Stroke Parakinesia Brachialis Oscitans: Clinical Insights from a Case Series.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

A Neuronal Perspective.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

Botulinum toxin-A use in paediatric hypertonia: Canadian practice patterns.

D Fehlings1, U Narayanan, J Andersen

  • 1Department of Paediatrics, University of Toronto, Toronto, Canada. dfehlings@hollandbloorview.ca

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|June 26, 2012
PubMed
Summary
This summary is machine-generated.

Canadian physicians largely follow best practices for botulinum toxin-A (BoNT-A) in treating pediatric hypertonia. Key areas for improvement include individualized goal setting and enhancing injection localization techniques for better outcomes.

More Related Videos

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy
07:20

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Related Experiment Videos

Last Updated: May 21, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy
07:20

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Area of Science:

  • Pediatric Neurology
  • Rehabilitation Medicine
  • Pharmacology

Background:

  • Hypertonia in children significantly impacts motor function and quality of life.
  • Botulinum toxin-A (BoNT-A) is a key therapeutic agent for managing pediatric hypertonia.
  • Assessing current clinical practices is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To evaluate Canadian physicians' current practices in administering BoNT-A for pediatric hypertonia.
  • To compare these practices against established international best practice recommendations.
  • To identify variations in clinical approaches and opportunities for knowledge translation.

Main Methods:

  • A cross-sectional electronic survey was distributed to 50 Canadian physicians.
  • Thirteen physicians participated in the survey development and analysis.
  • Survey responses from 78% of physicians provided data on assessment tools, indications, adverse events, dosage, localization, and pain management.

Main Results:

  • Common assessment tools included Gross Motor Function Classification System and Modified Tardieu Scale; goal-setting tools were rarely used.
  • Significant variability existed in BoNT-A use for hip displacement; localized weakness was the most common adverse event.
  • Electrical stimulation and ultrasound for localization were infrequently employed, while distraction was the primary pain management technique.

Conclusions:

  • Canadian physicians' use of BoNT-A for pediatric hypertonia generally aligns with international best practices.
  • Opportunities for knowledge translation include promoting individualized goal setting and improving localization techniques.
  • BoNT-A demonstrates a favorable safety profile in pediatric patients.